Reference entry
Erythropoietin (EPO) (EPO)
EPO · Red Blood Cell Stimulating Hormone
Overview
Erythropoietin (EPO) is an essential glycoprotein hormone that stimulates red blood cell production. Naturally produced by the kidneys in response to low oxygen levels, recombinant human EPO is FDA-approved for treating anemia in chronic kidney disease and chemotherapy patients. EPO binding to receptors on bone marrow…
EPO binds to erythropoietin receptors (EPOR) on erythroid progenitor cells in bone marrow, activating three interconnected signaling pathways: JAK2/STAT5, PI3K/AKT, and RAS/MAPK. This promotes survival of red blood cell precursors by protecting them from apoptosis, accelerates proliferation and differentiation of…
Primary FDA-approved indication for anemia secondary to chronic kidney disease.
FDA-approved for treating anemia in cancer patients receiving chemotherapy.
Used to reduce need for blood transfusions in certain surgical settings.
Mechanism
Erythropoietin (EPO) is an essential glycoprotein hormone that stimulates red blood cell production. Naturally produced by the kidneys in response to low oxygen levels, recombinant human EPO is FDA-approved for treating anemia in chronic kidney disease and chemotherapy patients. EPO binding to receptors on bone marrow…
EPO binds to erythropoietin receptors (EPOR) on erythroid progenitor cells in bone marrow, activating three interconnected signaling pathways: JAK2/STAT5, PI3K/AKT, and RAS/MAPK. This promotes survival of red blood cell precursors by protecting them from apoptosis, accelerates proliferation and differentiation of…
Primary FDA-approved indication for anemia secondary to chronic kidney disease.
Research areas
- Erythropoietin (EPO) is an essential glycoprotein hormone that stimulates red blood cell production. Naturally produced by the kidneys in response to low oxygen levels, recombinant human EPO is FDA-approved for treating anemia in chronic kidney disease and chemotherapy patients. EPO binding to receptors on bone marrow…
- EPO binds to erythropoietin receptors (EPOR) on erythroid progenitor cells in bone marrow, activating three interconnected signaling pathways: JAK2/STAT5, PI3K/AKT, and RAS/MAPK. This promotes survival of red blood cell precursors by protecting them from apoptosis, accelerates proliferation and differentiation of…
- Primary FDA-approved indication for anemia secondary to chronic kidney disease.
- FDA-approved for treating anemia in cancer patients receiving chemotherapy.
- Used to reduce need for blood transfusions in certain surgical settings.
Research notes
- Injection site reactions
- Severe headache or vision changes
- Chest pain or shortness of breath
- Signs of blood clots (leg swelling, pain)
- Sudden loss of response to EPO
Questions
Why is EPO banned in sports if it's FDA-approved as medicine?
EPO is FDA-approved specifically for anemia in kidney disease and chemotherapy patients—narrow medical indications. It's banned in sports because it boosts oxygen delivery far beyond medical therapeutic levels, providing unfair endurance advantages. The performance-enhancing effects at doses used by athletes vastly…
At what hemoglobin level does EPO become dangerous?
Medical guidelines recommend keeping hemoglobin below 11-12 g/dL during EPO therapy because higher levels significantly increase cardiovascular risks including blood clots, stroke, and heart attack. This ceiling exists because excessive oxygen-carrying capacity paradoxically becomes harmful, increasing blood viscosity…